The New England Journal of Medicine

COVID Vaccine

An mRNA Vaccine against SARS-CoV-2 — Preliminary Report

The severe acute respiratory syn- drome coronavirus 2 (SARS-CoV-2) emerged in December 2019 and spread globally, causing a pandemic of respiratory illness desig- nated coronavirus disease 2019 (Covid-19).1 The urgent need for vaccines prompted an interna- tional response, with more than 120 candidate SARS-CoV-2 vaccines in development within the first 5 months of 2020.2 The candidate vaccine mRNA-1273 is a lipid nanoparticle–encapsulated, nucleoside-modified messenger RNA (mRNA)– based vaccine that encodes the SARS-CoV-2 spike (S) glycoprotein stabilized in its prefusion confor- mation. The S glycoprotein mediates host cell attachment and is required for viral entry3; it is the primary vaccine target for many candidate SARS-CoV-2 vaccines.4-7

We conducted a first-in-human phase 1 clini- cal trial in healthy adults to evaluate the safety and immunogenicity of mRNA-1273. Here we re- port interim results of the trial.

Please download full article here.

Leave a reply